Document Detail

Bowels control brain: gut hormones and obesity.
Jump to Full Text
MedLine Citation:
PMID:  23092061     Owner:  NLM     Status:  MEDLINE    
Peptide hormones are released from the gastrointestinal tract in response to nutrients and communicate information regarding the current state of energy balance to the brain. These hormones regulate appetite, energy expenditure and glucose homeostasis. They can act either via the circulation at target peripheral tissues, by activation of the vagus nerve or by acting on key brain regions implicated in energy homeostasis such as the hypothalamus and brainstem. This review gives an overview of the main gut hormones implicated in the regulation of food intake and how some of these are being targeted to develop anti obesity treatments.
Gavin A Bewick
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Biochemia medica     Volume:  22     ISSN:  1330-0962     ISO Abbreviation:  Biochem Med (Zagreb)     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-24     Completed Date:  2012-11-27     Revised Date:  2014-01-26    
Medline Journal Info:
Nlm Unique ID:  9610305     Medline TA:  Biochem Med (Zagreb)     Country:  Croatia    
Other Details:
Languages:  eng     Pagination:  283-97     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Appetite / drug effects,  physiology
Eating / drug effects
Gastrointestinal Hormones / metabolism*,  therapeutic use
Obesity / drug therapy,  metabolism*
Peptide Hormones / metabolism,  therapeutic use
Grant Support
//Biotechnology and Biological Sciences Research Council; //Medical Research Council
Reg. No./Substance:
0/Gastrointestinal Hormones; 0/Peptide Hormones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Biochem Med (Zagreb)
Journal ID (iso-abbrev): Biochem Med (Zagreb)
Journal ID (publisher-id): Biochemia Medica
ISSN: 1330-0962
ISSN: 1846-7482
Publisher: Croatian Society of Medical Biochemistry and Laboratory Medicine
Article Information
Download PDF
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine
Received Day: 01 Month: 6 Year: 2012
Accepted Day: 11 Month: 9 Year: 2012
Electronic publication date: Day: 15 Month: 10 Year: 2012
collection publication date: Month: 10 Year: 2012
Volume: 22 Issue: 3
First Page: 283 Last Page: 297
PubMed Id: 23092061
ID: 3900054
Publisher Id: biochem_med-22-3-283-5

Bowels control brain: gut hormones and obesity
Gavin A. Bewick
Section of Investigative Medicine, Imperial College London, London, United Kingdom
Correspondence: Corresponding author:


Obesity is one of the greatest health care challenges of our time. Currently there are estimated to be 2 billion adults who are overweight worldwide (body mass index 25–30 kg/m2) and a further 500 million are obese (BMI greater than 30 kg/m2). Being overweight or obese carries an increased risk type 2 diabetes, ischaemic heart disease, stroke and cancer, and carries an increased risk of both all cause, and cause-specific mortality (1,2). This has prompted a concerted effort to identify effective novel treatments for obesity. The role of peripheral hormones and the gut/brain axis in the regulation of appetite has become a hot topic in recent years, owing to the growing global obesity crisis. Of particular interest has been the potential of these peripheral signals to provide novel targets for developing anti-obesity therapies. The focus of this review is to provide a synopsis of the gut-brain cross talk involved in the regulation of food intake.

Neuroendocrine control of appetite

The hypothalamus and the brainstem are the main central nervous system regions responsible for the regulation of energy homeostasis. Although it is important to remember these regions are not solely responsible. Both the hypothalamus and the brainstem receive peripheral neural and hormonal signals that relay information regarding energy availability, both acutely i.e. nutritional state and long term availability i.e. adiposity (3). Neural afferents and hormonal signals from the periphery are integrated with higher brain centre signals (e.g. relaying reward drive and mood) to regulate appetite and control energy expenditure (4) (Figure 1).

The arcuate nucleus (ARC) of the hypothalamus is believed to play a crucial role in the regulation of food intake and energy homeostasis. The ARC contains two populations of neurons with opposing effects on food intake (5). Orexigenic neurons (i.e. those stimulating appetite) express neuropeptide Y (NPY) and Agouti-related protein (AgRP) (68). Whilst anorexigenic neurons (i.e. those inhibiting appetite) in the ARC express alpha-melanocyte-stimulating hormone (alpha-MSH) derived from pro-opiomelanocortin (POMC), and cocaine-and amphetamine-regulated transcript (CART) (9).

The ARC is adjacent to the median eminence, a ‘circumventricular organ’ with fenestrated capillaries and hence an incomplete blood-brain barrier (10). Circulating hormones are able to pass across the median eminence and influence the activity of the ARC neurons directly. Gut hormones are released from the gastrointestinal tract on a meal to meal basis and signal short term nutrient availability to the ARC. Other circulating factors such as insulin and leptin (a circulating peptide released from adipose tissue) relay information about long-term energy stores and adiposity (11). Thus the ARC has been described as a conduit through which the body can balance its energy requirements to maintain weight.

Additionally short term availability of nutrients is signalled by gastrointestinal vagal afferents. Following a meal the vagus is activated by both mechanoreceptors and chemoreceptors. The resultant neural signals converge in the nucleus of the tractus solitarius (NTS) within the brainstem. These signal are then fed forward Neuronal from the NTS to the hypothalamus. Circulating factors such as gut hormones are also thought to act at the NTS, which like the ARC is adjacent to a circumventricular organ, the ‘area postrema’ (AP). For example, ablation of both the AP and another circumventricular organ, the subfornical organ (SFO), has been shown to delay the anorectic action of the gut hormone peptide tyrosine tyrosine (PYY) (12). Gut hormones also alter the activity of the ascending vagal pathways from the gut to the brainstem (13).

Hence, the hypothalamic ARC orexigenic and anorexigenic neurons are influenced by numerous neural and hormonal inputs. These ARC neurons in turn project to a number of extra-hypothalamic and intra-hypothalamic regions, including in particular the hypothalamic paraventricular nucleus (PVN), where some of the important efferent pathways regulating energy expenditure arise.

Enteroendocrine cells of the gastrointestinal tract

There are at least 15 different types of enteroendocrine cells diffusely distributed throughout the gastrointestinal epithelium (14). These cells produce and release a variety of hormones and signalling molecules, which together constitute the largest endocrine organ in the body (14,15). Chemosensing of gut luminal contents by the enteroendocrine GI cells plays a critical role in the control of functions such as digestion, pancreatic secretion, food intake, and metabolic regulation. Evidence that endocrine cells can directly sense luminal contents has been demonstrated in PYY and glucagon like peptide −1 (GLP-1) expressing L cells. Both human and rodent L cells express receptors previously identified in the oral epithelium for detecting sweet (T1R2 and T1R3) and bitter sensation (T2R), as well as amino acids (T1R1 and T1R3) (16,17). Additionally, the gustducin G protein which is associated with these taste receptors has been identified in L cells (16,17). Activation of these receptors is thought to lead to increased intracellular calcium and release of gastrointestinal peptides from enteroendocrine cells (17). The presence of the sweet taste receptor subunit T1R3 and gustducin may also underlie a luminal glucose sensing mechanism, since activation of these receptors mediates the postprandial release of GLP-1 from intestinal L cells (16).

Fatty acids derived from digestion of dietary fats appear to be sensed via separate mechanisms. The short-chain fatty acid receptors GPR43 and GPR41 are expressed in PYY-containing enteroendocrine L cells (18,19). Short chain fatty acids have been shown to increase both PYY and GLP-1 secretion in rats when delivered directly into the colon (20,21). GPR119 is another G protein coupled receptor found in intestinal endocrine cells as well as pancreatic beta cells (22). Administration of oleoylethanolamide (OEA), an endogenous long chain fatty acid derivative, and other GPR119 agonists increases GLP-1 secretion, both in vitro and in vivo in rodents (22,23).

The enteroendocrine L cells therefore have the capacity to integrate complex nutrient sensing in the gut and to respond appropriately by releasing gut hormones. In addition to chemical stimulation, the endocrine cells of the gut also respond to neural and physical stimulation of the cell by releasing peptide containing granules at the basolateral side of the cell. These peptides can have an endocrine role, a local paracrine role, and/or activate receptors present on nerves innervating the GI mucosa (24).

Gut hormones regulating food intake

The gastrointestinal tract releases more than 20 different regulatory peptide hormones that influence a number of physiological processes (25). The release of gut hormones such as PYY, GLP-1, and oxyntomodulin (OXM) is stimulated by distension of the stomach, production of nutrients from the digestion of food, and by neuronal signals (26,27).

Gut hormones are believed to contribute to the short-term feelings of satiety and hunger (28). These peptides are thought to reduce food intake by decreasing hypothalamic orexigenic signalling and increasing anorectic signalling (13,29). These peptides also mediate inhibitory feedback mechanisms on intestinal transit, contributing to prolonged gastric distension, and increased satiety between meals (30,31). These combined CNS effects and ‘intestinal brake’ mechanisms facilitate the control of food intake and postprandial transit through the gastrointestinal tract and thereby the immediate availability of energy. Below the focus of the review will concentrate on 5 of the most studied gut hormones which have been shown to control food intake and body weight and which are being actively pursued as anti-obesity targets.

Peptide tyrosine tyrosine (PYY)

PYY belongs to the ‘PP-fold’ family of proteins like NPY and pancreatic polypeptide (PP). These peptides are 36 amino acids in length and share a common tertiary structural motif known as the PP-fold. C-terminal amidation of these proteins is a necessary requirement for biological activity. PYY exists endogenously in two forms: PYY1-36 and PYY3-36(32). The enzymatic cleavage of secreted PYY1-36 at the amino terminal by the cell surface enzyme dipeptidyl peptidase IV (DPP-IV) gives rise to PYY3-36(33), which is the predominant form of circulating PYY immunoreactivity. PYY1-36 and PYY3-36 exert their effects through the neuropeptide Y family of receptors (34). PYY1-36 binds with similar affinity to all of the Y receptors, however PYY3-36 is a selective high affinity agonist at the Y2 receptor subtype (Y2R) (35). The Y2R is thought to be the receptor responsible for mediating the reduction of food intake by PYY. It is an auto-inhibitory pre-synaptic receptor found on NPY neurons within the ARC (36), and deficiency of the Y2R abolishes the anorectic effects of PYY (29). Furthermore, the anorectic effects of PYY3-36 are attenuated by Y2R antagonists (37). PYY3-36 is therefore thought to reduce food intake through activation of the Y2R.

Low levels of PYY are detected in enteroendocrine cells in the stomach, and levels increase distally along the small and large intestine, reaching their highest levels in cells in the colon and rectum (26). Endogenous circulating concentrations of PYY are lowest in the fasting state, and rise post-prandially in proportion to caloric intake (26). Plasma levels of PYY rise within 30 minutes of a meal, and in humans, circulating levels plateau at 1–2 hours post-prandially, remaining elevated for up to 6 hours (38). Protein rich meals cause the greatest increase in PYY levels compared to other macronutrients (39,40). Peripheral administration of PYY3-36 reduces food intake and weight gain in rodents (29,4143). Intravenous administration of PYY inhibits food intake in humans and unlike leptin is equally effective in normal and obese subjects (44).

The anorectic effects of PYY3-36 appear to be mediated centrally via the ARC, as peripheral administration of PYY3-36 increases c-fos expression in this hypothalamic nucleus (29). Peripheral administration has been reported to decrease expression and release of NPY whilst activating POMC neurons (29). However, others have reported PYY3-36 inhibits POMC neurons via postsynaptic Y2R (45). Moreover, POMC knockout mice maintain their acute anorectic response to peripherally administered PYY3-36, suggesting that POMC is not critical to the inhibitory effects of PYY3-36 on feeding (46).

A vagal brainstem mediated pathway may also be involved since PYY is expressed by the neurones of the myenteric plexus and the Y2R receptor is expressed by the vagus nerve (47). Furthermore the anorectic effect of PYY3-36 on both food intake (47,48), and ARC activation of feeding neurons, are abolished following bilateral sub-diaphragmatic total truncal vagotomy or following transection of the brainstem–hypothalamic pathway in rodents (48).

Interestingly, it has recently been shown that acute effects of gastrointestinal bypass surgery on body weight are lost in PyyKO mice (49), and that wild-type mice losing weight after gastrointestinal bypass surgery exhibit increased colonic Pyy expression and circulating fasting PYY levels (49). Suggesting PYY plays a key role in mediating the early weight loss that occurs following gastrointestinal bypass surgery.

The effects of PYY3-36 on satiety and central control of appetite are clear. Most are mediated via anorectic neuronal populations in the ARC, but vagal/brainstem-mediated pathways and peripheral effects of PYY on gastric emptying and intestinal motility may also play a part. High plasma concentrations of PYY result in nausea, but the importance of PYY3-36 at physiological levels in the regulation of energy intake make it a prime focus for new obesity therapies, targeted either at PYY itself, or against the Y2 receptor.

Glucagon-like peptide-1 (GLP-1)

GLP-1 is a 30 amino acid peptide produced from the cleavage of preproglucagon (50). The two bio-active forms of GLP-1, GLP-17-37 and GLP-17-36 amide, are released into the circulation from L cells of the gastrointestinal tract in response to an oral glucose load (51). Physiologically, GLP-1 is an important in-cretin, augmenting glucose-dependent insulin release (52). In addition, GLP-1 inhibits the secretion of glucagon, thereby inhibiting endogenous glucose production (53). The net effect is to reduce blood glucose following a meal. GLP-1 also delays gastric emptying (54), and increases satiety (55,56).

Like PYY, GLP-1 has been shown to act centrally at hypothalamic nuclei known to be implicated in the control of appetite including the ARC, PVN and supraoptic nucleus (57). Both acute peripheral and central administration of GLP-1 reduce food intake in rats (58,59) and chronic administration of GLP-1 reduces weight gain (55). The intravenous administration of GLP-1 to normal and obese humans decreases food intake in a dose dependent manner (60) as well as reducing gastric emptying (61,62). These effects are thought to be mediated through vagal and brainstem pathways since peripheral administration of GLP-1 activates neurons within the brainstem in rats (63). Furthermore, this increase in neuronal activity, and the anorectic effects of GLP-1, are abolished following vagotomy in rodents (48,63). More recently, functional magnetic resonance imaging (fMRI) has confirmed the activation of the VMH and PVN following peripheral administration of GLP-1 (64).

GLP-1 is rapidly degraded in the circulation by DPP-IV, making native GLP-1 unsuitable for therapeutic use. Longer acting GLP-1 mimetics have been developed (65). Exendin-4 is a naturally occurring GLP-1 mimetic isolated from the venom of Heloderma suspectum, a lizard native to several southwestern American states (66). A truncated form of this peptide, exendin 9–39, acts as a competitive antagonist at the GLP-1 receptor. Acute intracerebroventricular administration of exendin 9–39 increases food intake and chronic administration increases body weight in rats (55,59). Suggesting endogenous peripheral GLP-1 may physiologically reduce appetite and food intake. However, GLP-1 receptor knockout mice do not have altered food intake or body weight (67). This may be because developmental changes compensate for the lack of GLP-1 signalling, or may reflect that GLP-1 has a more important physiological role in controlling blood glucose than in regulating food intake.

The discovery of exendin-4 has led to the development of a synthetic version, exenatide. Exenatide has a much longer in vivo half-life than native GLP-1, stimulates insulin release, suppresses glucagon and lowers blood glucose. It is the first incretin mimetic approved for the treatment of type 2 diabetes (68). Exenatide has also been shown to reduce body weight in treated diabetics in phase III clinical trials (6971). The weight loss associated with exenatide is considered a significant advantage as many anti-diabetic treatments are commonly associated with weight gain. Nausea is a relatively common side effect of Exenatide treatment. However, it does not seem to be intrinsically linked to the effects on appetite (3). Whilst GLP-1 has been developed as a treatment for diabetes due to its incretin properties, the observed effects of GLP-1 on satiety and weight loss are a valuable secondary effect. Indeed recent data suggests liraglutide may be useful for the treatment of obesity, causing sustained weight loss over 2 years but with a 50% rate of nausea and vomiting in the 3.0 mg/day group in the first year (72). The newest long acting analogues of GLP-1, exenatide-LAR (Amylin Pharmaceuticals, FDA approved January 2012), taspoglutide (Ipsen and Roche) and Albiglutide (GlaxoSmithKline), have been shown to effectively control glucose and to reduce weight. These agents allow for less-frequent dosing schedules, improved glycemic control throughout the day, and improved treatment satisfaction compared to some available agents (73). It remains to be seen whether these drugs perform well enough in specific weight loss paradigms such that they could be used as anti-obesity agents.

Oxyntomodulin (OXM)

OXM, like GLP-1, is also a product of the preproglucagon precursor molecule. It is a 37 amino acid peptide released post-prandially from L cells in proportion to caloric intake (27). OXM delays gastric emptying and reduces gastric acid secretion (74), and has been shown acutely to decrease food intake and in the longer term to decrease weight gain in rodents (75,76). In addition, chronic administration of OXM produces greater weight loss compared to pair-fed controls, suggesting an increase in energy expenditure may also help to reduce body weight (77). OXM has been shown to reduce food intake in normal weight human volunteers when administered intravenously or subcutaneously (78). Given preprandially to obese subjects it reduces both food intake and body weight (79). As in rats, there is evidence that OXM may also increase energy expenditure in humans (80).

Although OXM has some agonist activity at the glucagon receptor, there is evidence that its anorectic effect is predominantly mediated via the GLP-1 receptor (75,81). The anorectic effects of OXM are abolished in GLP-1 receptor knockout mice (81) and in the presence of the GLP-1 receptor antagonist exendin 9–39 (76). OXM has a 50-fold lower affinity for the GLP-1 receptor than GLP-1 itself, but despite this, it reduces food intake with similar potency (75). Furthermore, although the administration of exendin 9–39 directly into the ARC blocks the anorectic effects of OXM, it does not block those of GLP-1 (76). Therefore, it is possible that OXM may act via an as yet unidentified receptor. Studies using manganese-enhanced magnetic resonance imaging MRI (MEMRI) has shown that intraperitoneal administration of OXM produces a distinct pattern of neuronal activation compared to GLP-1 (82), implying that these two hormones act via different hypothalamic pathways.


Glucagon is a 29 amino acid peptide secreted from the α-cells of the pancreatic islets of Langerhans. It is a further product of preproglucagon cleavage alongside OXM and GLP-1. Glucagon is released into the portal vein in fasted states and also in response to exercise, and acts on the liver to promote hepatic glycogenolysis and gluconeogenesis and maintain glycaemic balance (8386).

Glucagon mediates its effects via the glucagon receptor, a 7-transmembrane G-protein coupled receptor which has a wide tissue distribution. It is expressed in the gut, adrenal glands, brain, heart, pancreas, spleen and in adipocytes, but is predominantly found in the liver and kidney (87).

As a potential treatment for obesity, glucagon has been shown to increase energy expenditure in rats, and also in humans during insulin deficiency (88). It also significantly reduces food intake, with a subjective reduction of appetite in man (89). Infusion of glucagon into the portal vein but not the inferior vena cava causes a reduction in meal size in rats (90).

Glucagon presents an interesting prospect in the treatment of obesity due to its effect on increasing energy expenditure, and increasing satiety. It has been demonstrated that the potentially unfavourable effect on glucose tolerance due to glucagon’s actions on hepatic glycogenolysis and gluconeogenesis is effectively counteracted by dual agonism at the glucagon and GLP-1 receptors (91,92). The data from these studies demonstrated highly effective weight loss in diet-induced obese mice whilst avoiding the hyperglycaemia that might be expected from agonism at the glucagon receptor.


Ghrelin is a 28-amino acid acylated peptide secreted from the stomach. It was originally identified as an endogenous ligand for the ‘growth hormone secretagogue’ receptor (GHS-R) and is a growth-hormone-releasing peptide (93).

Ghrelin is the only orexigenic gut hormone (94), causing an increase in food intake and weight gain in rodents following both peripheral and central administration (9597). Intravenous administration of ghrelin has also been shown to stimulate gastric acid secretion and motility in rats (98). In normal subjects, ghrelin levels are highest in the fasted state (99), and levels are chronically higher in people with weight loss due to anorexia nervosa or dietary reduction (100102). In contrast to other gut hormones, plasma ghrelin levels decrease after meals (100,103) and are low in obese subjects (102). Ghrelin concentrations are also reduced after gastric bypass surgery, and this may contribute to weight loss in such patients (101).

Ghrelin receptors are found in the ARC of the hypothalamus suggesting a central mode of action. Consistent with this c-fos expression is increased in the ARC after peripheral administration of ghrelin (104) and ablation of the ARC blocks ghrelin induced food intake (105). When given centrally, ghrelin also stimulates c-fos expression in other nuclei known to be involved in appetite control including the PVN, dorsomedial nucleus, and lateral hypothalamus as well as in the AP and NTS in the brainstem (95). Ghrelin and its receptor are both expressed in vagal afferents in mice (106), and blockade of the gastric vagal afferent has been shown to abolish ghrelin-induced feeding, growth hormone secretion, and activation of NPY-producing and growth hormone-releasing hormone producing neurons in rats suggesting an additional mode of action (107).

Diet induced obesity is associated with a blunting of ghrelin’s orexigenic effect. There has therefore been recent interest in the interaction between the ghrelin system and macronutrients. High fat feeding has been shown to render NPY/AgRP neurones relatively ghrelin resistant (108), and diets high in fat have been shown to directly inhibit the hyperphagic effect of ghrelin (109,110). These data have significant implications for developing anti-obesity treatments targeting the ghrelin system and suggest success of these approaches could depend on the fat content of the diet the patient consumes. More recently, ghrelin has been shown to engage neurons in the ventral tegmental area of the brain and may provide a link between the gut and neuronal control of stress-induced eating of ‘comfort foods’ (111).

Other gut peptides

A number of other gut-derived peptides have been shown to reduce food intake. However, the physiological role of these peptides in the regulation of food intake and energy homeostasis remains unclear.

CCK is released post-prandially from the small intestine (3), and has also been shown to co-localise with PYY in L cells (112) Two types of CCK receptor have been identified in the CNS and peripheral tissues CCK1 and 2 (113). CCK is released post-prandially in response to saturated fat, long-chain fatty acids, amino acids and small peptides that would normally result from protein digestion (114,115). CCK release and signalling via the CCK-1 receptors in response to these long chain fatty acids mediates stimulation of PYY release and inhibition of ghrelin (an orexigenic gut hormone) in human subjects (116).

The effects of CCK on appetite are well documented. Peripheral administration of CCK in rodents results in a dose dependant reduction in food intake, decreasing both meal size and duration (117). CCK administration is also associated with an increase in postprandial satiety behaviours such as increased grooming and decreased locomotor activity (117). In humans, intravenous administration of physiological doses of CCK reduces food intake and increases the perception of fullness (118). Unfortunately, the therapeutic potential of CCK as a treatment for obesity is limited by nausea and tachyphylaxis of the anorectic effects associated with chronic administration (119).

PP is an amidated 36-amino acid peptide and belongs to the ‘PP fold’ family of peptides. It is released post-prandially under vagal control by pancreatic islet PP cells (120122). PP binds to all the members of the Y receptor family, but has the highest affinity for the Y4 receptor subtype (123). The effects of PP are likely to be mediated by both the hypothalamus and brainstem (124). PP is comparable to other anorectic intestinal peptides such as PYY, being secreted in proportion to caloric intake. Circulating levels rise after meals and remain elevated for up to 6 hours post-prandially (120). Intraperitoneal injection of PP acutely reduces food intake in fasted mice (124), an effect that remains apparent for 24 hours after injection. Furthermore, chronic administration of PP over 6 days in ob/ob mice significantly reduces body weight gain and improves glucose profile (124). Intravenous infusion of PP at doses that achieve normal post-prandial plasma concentrations reduces appetite in lean humans and inhibition of food intake persists for 24 hours after infusion (125). PP has also been shown to reduce food intake at lower infusion rates (126). Furthermore, pancreatic polypeptide has been shown to reduce food intake in patients with obesity secondary to Prader-Willi syndrome (127). Additionally, PP has also been implicated in energy homeostasis, with exogenous administration of PP causing an increase in oxygen consumption (124), thus implying that part of the effect of PP on body weight may be due to increased energy expenditure. It has also been shown to increase spontaneous locomotor activity in mice (128). These data have lead to a concerted effort to develop long acting PP analogues, which have completed Phase I trials (129).

NT was first isolated from hypothalamic tissue, but is widely distributed throughout the central nervous system. However, the majority of NT is found within enteroendocrine cells of the GI tract (130). NT regulates a number of digestive processes, including gastrointestinal motility, and pancreatic and biliary secretion (131). It also has trophic effects on the pancreas and small intestine (132,133). Plasma levels of NT increase after a meal, with intraluminal fat being the most potent stimulus (134). Peripheral administration of neurotensin decreases food intake and grooming behaviour in rats only at large doses (135). Therefore at physiological levels, neurotensin is unlikely to play a major role in appetite regulation. Although neurotensin acutely reduces food intake when administered centrally in rats or peripherally in mice, chronic administration to mice has no significant effect on food intake or body weight (136). The lack of chronic effects on body weight suggests that NT is unlikely to be useful as a treatment for obesity.

Intracerebroventricular injection of glucagon-like peptide-2 (GLP-2) into rats inhibits food intake. In contrast, GLP-2 administered peripherally does not inhibit food intake in rodents or humans (137,138). GLP-2 appears to play a more important physiological role as an intestinal growth factor (138).

Amylin is a peptide co-secreted with insulin by pancreatic beta cells. Injection of amylin or amylin agonist has been shown to reduce food intake in a number of species, including humans (139143). The amylin receptor agonist pramlintide has been shown to cause weight loss in diabetic humans (141,143).

Vasoactive intestinal polypeptide (VIP) has been shown to reduce appetite, in addition to its well-characterized effects on the cardiovascular system and gastrointestinal motility and secretion. Intracerebroventricular administration of VIP has been shown to cause a potent short-lived decrease in food intake and an increase in activity and energy expenditure in rats. Treatment of hypothalamic explants with VIP stimulated the release of the anorexigenic peptide α-MSH (144). These studies suggest a possible endogenous role for VIP in the hypothalamic control of energy homeostasis.

Gut hormones and the treatment of obesity

Lifestyle and dietary modification alone are inadequate for the successful treatment of the majority of obese individuals. However, despite an increasingly high demand for intervention, the field of obesity therapeutics has limited options to offer these patients. The history of obesity pharmacotherapy is littered with examples of drugs withdrawn from the market due to adverse effects outweighing the beneficial effects of weight loss. Recent examples include Sibutramine, a norepinephrine and serotonin reuptake inhibitor, and Rimonabant, which is a cannabinoid-1 receptor blocker. Sibutramine was withdrawn after it was found to increase heart rate and blood pressure in some subjects, and was associated with an increased risk of stroke and non-fatal myocardial infarction in patients with pre-existing cardiovascular conditions (145), whilst Rimonabant was withdrawn amidst concerns regarding adverse psychiatric events (146). The only currently licensed product in the UK is Orlistat, a pancreatic lipase inhibitor which prevents fat absorption and confers a modest weight loss of 2.9 kg more than placebo over the course of a year (147).

The only obesity treatment that has been shown to confer long-term, sustained weight loss and a decrease in overall mortality is bariatric surgical intervention (148,149). Several surgical procedures are available to achieve weight loss. Gastric banding restricts the amount of food that can be comfortably ingested and increases the satiating effect of food (150). A more efficient reduction in appetite and weight loss is seen with surgical procedures that involve gastrointestinal bypass, such as Roux-en-Y Gastric bypass (RYGB) (148,149,151). Weight loss is normally associated with reduced plasma levels of the adipocyte-derived anorectic hormone leptin, causing increased hunger (152). However, following RYGB, despite significant reductions in body weight and leptin levels, appetite is markedly reduced (151). It has now been demonstrated that RYGB is more effective than either standard or intensive medical therapy in achieving glycaemic control and remission in patients with Type 2 diabetes (T2DM) (153,154). These seminal studies raise the question as to whether bariatric surgery could become a more important treatment for T2DM than medical therapy. Indeed, in a recent positional paper the International Diabetes Federation supported the selective use of various bariatric procedures for obese individuals with medically resistant T2DM (155). However, significant questions remain, not least is how long do these effects last? But also include when is the best time for surgical intervention? Does bariatric surgery work for everyone? What are the surgical/risk benefits in moderately obese patients? This list is by no means exhaustive. Given RYGB requires major surgery, which has inherent risk and is expensive, there is considerable effort aimed at determining how RYGB and other surgeries induce sustained weight loss and resolution of T2DM.

Of particular interest has been the suggestion that RYGB ameliorates coexistent type 2 diabetes mellitus before substantial weight loss has occurred and more rapidly than gastric banding. The differences between gastric banding and RYGB may be due to alterations in the anorectic and incretin gut hormone profile that is seen following RYGB, but not following gastric banding (156,157). Experimental evidence suggests that these anorectic gut hormones may mediate the effects of RYGB on appetite and body weight (157,158). Post-prandial PYY and GLP-1 levels begin to rise as early as 2 days following gastric bypass in humans (158), and secretory products of enteroendocrine L-cells, including PYY and GLP-1 remain elevated two years after bypass surgery (159). Inhibiting gut hormone release with somatostatin analogue octreotide increases the food intake after gastric bypass surgery but not following gastric banding (158), further suggesting that these hormones play a critical role. In rodent models of bariatric surgery increases in circulating GLP-1 (160) and PYY and a reduction in ghrelin (49), have been implicated in mediating the beneficial effects of these surgeries. Determining the mechanisms behind the sustained reduction in appetite may identify pathways that can be targeted by anti-obesity agents. To this end there has been recent concerted effort to mimic the rise in gut hormones following gut bypass by either the development of peptide based analogues or by the design of small molecule drugs which target nutrient sensing receptors on the enteroendocrine L-cell.

Long acting versions of PYY and OXM are being actively pursued by the pharmaceutical industry, such as Pfizer’s OAP-189, we await the dissemination of data from ongoing trials. In addition Given that gut hormones are co-released one logical approach would be the development of combination therapies. Indeed data suggests that co-administration of gut hormones can have additive effects on food intake inhibition, for example PYY + GLP-1 (161) or PYY + OXM (162). Such combination approaches may prove more effective than individual administration. Very recently the development of chimeric agonists has emerged as a novel form of combination therapy (91,92). GLP-1/glucagon co-agonists combine the appetite suppressive effects of GLP-1 and glucagon with the energy expenditure promoting effects of glucagon. Whilst at the same time GLP-1’s insulinotropic effects inhibit the detrimental hyperglycaemic effects of glucagon. Marcadia Ltd., now a subsidiary of Roche, first reported the beneficial effects of this approach and their compound is now undergoing clinical trials. In addition, Zealand Pharma is also developing a similar compound, ZP-2929, in partnership with Boehringer Mannheim. Time will tell if the promising pre-clinical data translates in to clinical benefit (163).

Considerable energy has also been directed toward the development of gut hormone secretagogues. The most well characterised class being agonists of GPR119. These compounds have been shown to release both GLP-1 and PYY (22). Their anti-diabetic effects are well defined; stimulation of GLP-1 and a direct insulinotropic action (22,164). It is less clear if these compounds will be effective as anti-obesity agents, but some agonists have been shown to significantly reduce food intake, for example PSN632408 (165). GPR119 is currently the only target for which synthetic modulators stimulate both incretin and insulin release. This highly beneficial profile has generated great industry interest with at least 9 companies actively working in this area. Initial clinical trials have been successful with respect to the anti-diabetic indication (166,167).


Obesity has emerged as a major global healthcare challenge. The significant mortality and morbidity associated with obesity has inspired a vast amount of research directed towards developing safe and efficacious weight-loss agents. The beneficial effects of centrally acting weight-loss agents have been negated by their potentially hazardous effects on mood, reward, dependence and autonomic tone. Gut hormones, as outlined in this article, play an important role in the homeostatic control of food intake and offer an alternative to centrally acting drugs. We believe that in time these approaches will develop clinically useful compounds which will offer a real answer to the ever growing burden of obesity.


Potential conflict of interest

None declared.

Investigative Medicine is funded by the MRC, BBSRC, NIHR, an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7- HEALTH-2009-241592 EuroCHIP grant and by the NIHR Imperial Biomedical Research Centre Funding Scheme. GAB is funded by an NIHR Career Development Fellowship.

1.. Whitlock G,Lewington S,Sherliker P,Clarke R,Emberson J,Halsey J,et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesLancetYear: 200937310839619299006
2.. Zheng W,McLerran DF,Rolland B,Zhang X,Inoue M,Matsuo K,et al. Association between body-mass index and risk of death in more than 1 million AsiansN Engl J MedYear: 20113647192921345101
3.. Murphy KG,Dhillo WS,Bloom SR. Gut peptides in the regulation of food intake and energy homeostasisEndocr RevYear: 2006277192717077190
4.. Schwartz MW,Woods SC,Porte D Jr,Seeley RJ,Baskin DG. Central nervous system control of food intakeNatureYear: 20004046617110766253
5.. Chaudhri OB,Field BC,Bloom SR. Gastrointestinal satiety signalsJ Obes (Lond)Year: 200832Suppl 7S2831
6.. Bewick GA,Gardiner JV,Dhillo WS,Kent AS,White NE,Webster Z,et al. Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotypeFASEB JYear: 2005191680216099943
7.. Broberger C,Johansen J,Johansson C,Schalling M,Hökfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and mono-sodium glutamate-treated miceProc Natl Acad Sci USAYear: 1998951504389844012
8.. Hahn TM,Breininger JF,Baskin DG,Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neuronsNat NeurosciYear: 19981271210195157
9.. Elias CF,Lee C,Kelly J,Aschkenasi C,Ahima RS,Couceyro PR,et al. Leptin activates hypothalamic CART neurons projecting to the spinal cordNeuronYear: 1998211375859883730
10.. Peruzzo B,Pastor FE,Blázquez JL,Schöbitz K,Peláez B,Amat P,et al. A second look at the barriers of the medial basal hypothalamusExp Brain ResYear: 2000132102610836632
11.. Porte D Jr,Baskin DG,Schwartz MW. Leptin and insulin action in the central nervous systemNutr RevYear: 200260S209 discussion S68–84, 85–7.. 12403080
12.. Baraboi ED,Michel C,Smith P,Thibaudeau K,Ferguson AV,Richard D. Effects of albumin-conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerveEur J NeurosciYear: 2010328263920646064
13.. Jobst EE,Enriori PJ,Cowley MA. The electrophysiology of feeding circuitsTrends Endocrinol MetabYear: 2004154889915541648
14.. Sjolund K,Sanden G,Hakanson R,Sundler F. Endocrine cells in human intestine: an immunocytochemical studyGastroenterologyYear: 1983851120306194039
15.. Cheng H,Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell typesAm J AnatYear: 1974141537614440635
16.. Jang HJ,Kokrashvili Z,Theodorakis MJ,Carlson OD,Kim BJ,Zhou J,et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1Proc Natl Acad Sci USAYear: 2007104150697417724330
17.. Rozengurt N,Wu SV,Chen MC,Huang C,Sternini C,Rozengurt E. Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colonAm J Physiol Gastrointest Liver PhysiolYear: 2006291G79280216728727
18.. Karaki S,Mitsui R,Hayashi H,Kato I,Sugiya H,Iwanaga T,Furness JB,Kuwahara A. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestineCell Tissue ResYear: 20063243536016453106
19.. Tazoe H,Otomo Y,Karaki S,Kato I,Fukami Y,Terasaki M,et al. Expression of short-chain fatty acid receptor GPR41 in the human colon 2Biomed ResYear: 2009301495619574715
20.. Cherbut C,Ferrier L,Rozé C,Anini Y,Blottière H,Lecannu G,Galmiche JP. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the ratAm J PhysiolYear: 1998275G1415229843779
21.. Fu-Cheng X,Anini Y,Chariot J,Voisin T,Galmiche JP,Rozé C. Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in ratsPflugers ArchYear: 199543166758584419
22.. Chu ZL,Carroll C,Alfonso J,Gutierrez V,He H,Lucman A,et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide releaseEndocrinologyYear: 200814920384718202141
23.. Lauffer LM,Iakoubov R,Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cellDiabetesYear: 20095810586619208912
24.. Cummings DE,Overduin J. Gastrointestinal regulation of food intakeJ Clin InvestYear: 2007117132317200702
25.. Murphy KG,Bloom SR. Gut hormones and the regulation of energy homeostasisNatureYear: 2006444854917167473
26.. Adrian TE,Ferri GL,Bacarese-Hamilton AJ,Fuessl HS,Polak JM,Bloom SR. Human distribution and release of a putative new gut hormone, peptide YYGastroenterologyYear: 1985891070773840109
27.. Le Quellec A,Kervran A,Blache P,Ciurana AJ,Bataille D. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastroneJ Clin Endocrinol MetabYear: 199274140591592887
28.. Badman MK,Flier JS. The gut and energy balance: visceral allies in the obesity warsScienceYear: 200530719091415790843
29.. Batterham RL,Cowley MA,Small CJ,Herzog H,Cohen MA,Dakin CL,et al. Gut hormone PYY(3-36) physiologically inhibits food intakeNatureYear: 2002418650412167864
30.. Lin HC,Zhao XT,Wang L,Wong H. Fat-induced ileal brake in the dog depends on peptide YYGastroenterologyYear: 1996110149158613054
31.. Wen J,Phillips SF,Sarr MG,Kost LJ,Holst JJ. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colonAm J PhysiolYear: 1995269G945528572226
32.. Grandt D,Schimiczek M,Beglinger C,Layer P,Goebell H,Eysselein VE,et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36Regul PeptYear: 19945115198059011
33.. Medeiros MD,Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11EndocrinologyYear: 19941342088947908871
34.. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptideRegul PeptYear: 199665165748897639
35.. Grandt D,Teyssen S,Schimiczek M,Reeve JR Jr,Feth F,Rascher W,et al. Novel generation of hormone receptor specificity by amino terminal processing of peptide YYBiochem Biophys Res CommunYear: 199218612993061324662
36.. Broberger C,Landry M,Wong H,Walsh JN,Hökfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleusNeuroendocrinologyYear: 1997663934089430445
37.. Abbott CR,Small CJ,Kennedy AR,Neary NM,Sajedi A,Ghatei MA,et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intakeBrain ResYear: 200510431394415862527
38.. Batterham RL,Bloom SR. The gut hormone peptide YY regulates appetiteAnn N Y Acad SciYear: 2003994162812851312
39.. Batterham RL,Heffron H,Kapoor S,Chivers JE,Chandarana K,Herzog H,et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulationCell MetabYear: 200642233316950139
40.. Pedersen-Bjergaard U,Host U,Kelbaek H,Schifter S,Rehfeld JF,Faber J,et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in manScand J Clin Lab InvestYear: 1996564975038903111
41.. Challis BG,Pinnock SB,Coll AP,Carter RN,Dickson SL,O’Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouseBiochem Biophys Res CommunYear: 2003311915914623268
42.. Chelikani PK,Haver AC,Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in ratsEndocrinologyYear: 20051468798815539554
43.. Vrang N,Madsen AN,Tang-Christensen M,Hansen G,Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesityAm J Physiol Regul Integr Comp PhysiolYear: 2006291R3677516914421
44.. Batterham RL,Cohen MA,Ellis SM,Le Roux CW,Withers DJ,Frost GS,et al. Inhibition of food intake in obese subjects by peptide YY3-36N Engl J MedYear: 2003349941812954742
45.. Ghamari-Langroudi M,Colmers WF,Cone RD. PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptorsCell MetabYear: 20052191916154101
46.. Challis BG,Coll AP,Yeo GS,Pinnock SB,Dickson SL,Thresher RR,et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3-36Proc Natl Acad Sci USAYear: 2004101469570015070780
47.. Koda S,Date Y,Murakami N,Shimbara T,Hanada T,Toshinai K,et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in ratsEndocrinologyYear: 200514623697515718279
48.. Abbott CR,Monteiro M,Small CJ,Sajedi A,Smith KL,Parkinson JR,et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathwayBrain ResYear: 200510441273115862798
49.. Chandarana K,Gelegen C,Karra E,Choudhury AI,Drew ME,Fauveau V,et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YYDiabetesYear: 201160810821292870
50.. Dhanvantari S,Seidah NG,Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagonMol EndocrinolYear: 199610342558721980
51.. Herrmann C,Göke R,Richter G,Fehmann HC,Arnold R,Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrientsDigestionYear: 199556117267750665
52.. MacDonald PE,El-Kholy W,Riedel MJ,Salapatek AM,Light PE,Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretionDiabetesYear: 200251Suppl 3S4344212475787
53.. Willms B,Werner J,Holst JJ,Orskov C,Creutzfeldt W,Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patientsJ Clin Endocrinol MetabYear: 199681327328550773
54.. Schirra J,Nicolaus M,Roggel R,Katschinski M,Storr M,Woerle HJ,et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humansGutYear: 2006552435115985560
55.. Meeran K,O’Shea D,Edwards CM,Turton MD,Heath MM,Gunn I,et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the ratEndocrinologyYear: 1999140244509886831
56.. Punjabi M,Arnold M,Geary N,Langhans W,Pacheco-López G. Peripheral glucagon-like peptide-1 (GLP-1) and satiationPhysiol BehavYear: 201110571621371486
57.. Shughrue PJ,Lane MV,Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamusEndocrinologyYear: 19961375159628895391
58.. Tang-Christensen M,Vrang N,Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviourInt J Obes Relat Metab DisordYear: 200125Suppl 5S42711840214
59.. Turton MD,O’Shea D,Gunn I,Beak SA,Edwards CM,Meeran K,et al. A role for glucagon-like peptide-1 in the central regulation of feedingNatureYear: 199637969728538742
60.. Verdich C,Flint A,Gutzwiller JP,Näslund E,Beglinger C,Hellström PM,et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humansJ Clin Endocrinol MetabYear: 2001864382911549680
61.. Näslund E,Bogefors J,Skogar S,Grybäck P,Jacobsson H,Holst JJ,et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humansAm J PhysiolYear: 1999277R910610484511
62.. Nauck MA,Niedereichholz U,Ettler R,Holst JJ,Orskov C,Ritzel R,et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAm J PhysiolYear: 1997273E98189374685
63.. Imeryüz N,Yeğen BC,Bozkurt A,Coşkun T,Villanueva-Peñacarrillo ML,Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanismsAm J PhysiolYear: 1997273G92079357836
64.. Parkinson JR,Chaudhri OB,Kuo YT,Field BC,Herlihy AH,Dhillo WS,et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI)NeuroimageYear: 20094410223118983926
65.. Joy SV,Rodgers PT,Scates AC. Incretin mimetics as emerging treatments for type 2 diabetesAnn PharmacotherYear: 200539110815562141
66.. Eng J,Kleinman WA,Singh L,Singh G,Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreasJ Biol ChemYear: 1992267740251313797
67.. Drucker DJ. The biology of incretin hormonesCell MetabYear: 200631536516517403
68.. Drucker DJ,Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancetYear: 2006368169670517098089
69.. Buse JB,Henry RR,Han J,Kim DD,Fineman MS,Baron AD,et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes CareYear: 20042726283515504997
70.. DeFronzo RA,Ratner RE,Han J,Kim DD,Fineman MS,Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes CareYear: 200528109210015855572
71.. Kendall DM,Riddle MC,Rosenstock J,Zhuang D,Kim DD,Fineman MS,Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes CareYear: 20052810839115855571
72.. Astrup A,Carraro R,Finer N,Harper A,Kunesova M,Lean ME,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInt J Obes (Lond)Year: 2012368435421844879
73.. Tzefos M,Harris K,Brackett A. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adultsAnn PharmacotherYear: 201246687822232377
74.. Schjoldager B,Mortensen PE,Myhre J,Christiansen J,Holst JJ. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functionsDig Dis SciYear: 198934141192670487
75.. Dakin CL,Gunn I,Small CJ,Edwards CM,Hay DL,Smith DM,et al. Oxyntomodulin inhibits food intake in the ratEndocrinologyYear: 200114242445011564680
76.. Dakin CL,Small CJ,Batterham RL,Neary NM,Cohen MA,Patterson M,et al. Peripheral oxyntomodulin reduces food intake and body weight gain in ratsEndocrinologyYear: 200414526879515001546
77.. Dakin CL,Small CJ,Park AJ,Seth A,Ghatei MA,Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed ratsAm J Physiol Endocrinol MetabYear: 2002283E1173712388165
78.. Cohen MA,Ellis SM,Le Roux CW,Batterham RL,Park A,Patterson M,et al. Oxyntomodulin suppresses appetite and reduces food intake in humansJ Clin Endocrinol MetabYear: 200388469670114557443
79.. Wynne K,Park AJ,Small CJ,Patterson M,Ellis SM,Murphy KG,et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trialDiabetesYear: 2005542390516046306
80.. Wynne K,Park AJ,Small CJ,Meeran K,Ghatei MA,Frost GS,Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trialInt J Obes (Lond)Year: 20063017293616619056
81.. Baggio LL,Huang Q,Brown TJ,Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditureGastroenterologyYear: 20041275465815300587
82.. Chaudhri OB,Parkinson JR,Kuo YT,Druce MR,Herlihy AH,Bell JD,et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imagingBiochem Biophys Res CommunYear: 200635029830617007819
83.. Striffler J,Cardell EL,Cardell RR Jr. Effects of glucagon on hepatic glycogen and smooth endoplasmic reticulumAm J AnatYear: 1981160363797282565
84.. Studer RK,Snowdowne KW,Borle AB. Regulation of hepatic glycogenolysis by glucagon in male and female rats. Role of cAMP and Ca2+ and interactions between epinephrine and glucagonJ Biol ChemYear: 198425935966046323432
85.. Stevenson RW,Steiner KE,Davis MA,Hendrick GK,Williams PE,Lacy WW,et al. Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivoDiabetesYear: 19873638292879758
86.. Wasserman DH,Spalding JA,Bracy D,Lacy DB,Cherrington AD. Exercise-induced rise in glucagon and keto-genesis during prolonged muscular workDiabetesYear: 1989387998072566546
87.. Svoboda M,Tastenoy M,Vertongen P,Robberecht P. Relative quantitative analysis of glucagon receptor mRNA in rat tissuesMol Cell EndocrinolYear: 199410513177859919
88.. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiencyJ Clin Endocrinol MetabYear: 1987648969012881943
89.. Schulman JL,Carleton JL,Whitney G,Whitehorn JC. Effect of glucagon on food intake and body weight in manJ Appl PhysiolYear: 1957114192113480952
90.. Geary N,Le Sauter J,Noh U. Glucagon acts in the liver to control spontaneous meal size in ratsAm J PhysiolYear: 1993264R116228430871
91.. Pocai A,Carrington PE,Adams JR,Wright M,Eiermann G,Zhu L,et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in miceDiabetesYear: 20095822586619602537
92.. Day JW,Ottaway N,Patterson JT,Gelfanov V,Smiley D,Gidda J,et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodentsNat Chem BiolYear: 200957495719597507
93.. Kojima M,Hosoda H,Date Y,Nakazato M,Matsuo H,Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach.NatureYear: 19994026566010604470
94.. Bewick GA,Kent A,Campbell D,Patterson M,Ghatei MA,Bloom SR,Gardiner JV. Mice with hyperghrelinemia are hyperphagic and glucose intolerant and have reduced leptin sensitivityDiabetesYear: 200958840619151202
95.. Lawrence CB,Snape AC,Baudoin FM,Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centersEndocrinologyYear: 20021431556211751604
96.. Tschöp M,Smiley DL,Heiman ML. Ghrelin induces adiposity in rodentsNatureYear: 20004079081311057670
97.. Wren AM,Small CJ,Ward HL,Murphy KG,Dakin CL,Taheri S,et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretionEndocrinologyYear: 20001414325811089570
98.. Masuda Y,Tanaka T,Inomata N,Ohnuma N,Tanaka S,Itoh Z,et al. Ghrelin stimulates gastric acid secretion and motility in ratsBiochem Biophys Res CommunYear: 2000276905811027567
99.. Toshinai K,Mondal MS,Nakazato M,Date Y,Murakami N,Kojima M,et al. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administrationBiochem Biophys Res CommunYear: 20012811220511243865
100.. Ariyasu H,Takaya K,Tagami T,Ogawa Y,Hosoda K,Akamizu T,et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humansJ Clin Endocrinol MetabYear: 2001864753811600536
101.. Cummings DE,Weigle DS,Frayo RS,Breen PA,Ma MK,Dellinger EP,Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgeryN Engl J MedYear: 200234616233012023994
102.. Shiiya T,Nakazato M,Mizuta M,Date Y,Mondal MS,Tanaka M,et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretionJ Clin Endocrinol MetabYear: 200287240411788653
103.. Tschöp M,Wawarta R,Riepl RL,Friedrich S,Bidlingmaier M,Landgraf R,Folwaczny C. Post-prandial decrease of circulating human ghrelin levelsJ Endocrinol InvestYear: 200124RC192111434675
104.. Hewson AK,Dickson SL. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed ratsJ NeuroendocrinolYear: 2000121047911069119
105.. Tamura H,Kamegai J,Shimizu T,Ishii S,Sugihara H,Oikawa S. Ghrelin stimulates GH but not food intake in arcuate nucleus ablated ratsEndocrinologyYear: 200214332687512193538
106.. Page AJ,Slattery JA,Milte C,Laker R,O’Donnell T,Dorian C,et al. Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferentsAm J Physiol Gastrointest Liver PhysiolYear: 2007292G13768417290011
107.. Date Y,Murakami N,Toshinai K,Matsukura S,Niijima A,Matsuo H,et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in ratsGastroenterologyYear: 20021231120812360474
108.. Briggs DI,Enriori PJ,Lemus MB,Cowley MA,Andrews ZB. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neuronsEndocrinologyYear: 201015147455520826561
109.. Gardiner JV,Campbell D,Patterson M,Kent A,Ghatei MA,Bloom SR,Bewick GA. The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fatGastroenterologyYear: 201013824687620178795
110.. Perez-Tilve D,Heppner K,Kirchner H,Lockie SH,Woods SC,Smiley DL,et al. Ghrelin-induced adiposity is independent of orexigenic effectsFASEB JYear: 20112528142221543764
111.. Chuang JC,Perello M,Sakata I,Osborne-Lawrence S,Savitt JM,Lutter M,Zigman JM. Ghrelin mediates stress-induced food-reward behavior in miceJ Clin InvestYear: 201112126849221701068
112.. Roth KA,Kim S,Gordon JI. Immunocytochemical studies suggest two pathways for enteroendocrine cell differentiation in the colonAm J PhysiolYear: 1992263G174801514628
113.. Moran TH,Robinson PH,Goldrich MS,McHugh PR. Two brain cholecystokinin receptors: implications for behavioral actionsBrain ResYear: 198636217593002550
114.. Liddle RA,Goldfine ID,Rosen MS,Taplitz RA,Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contractionJ Clin InvestYear: 1985751144522580857
115.. Rehfeld JF,Bungaard JR,Friis-Hansen L,Goetze JP. On the tissue-specific processing of procholecystokinin in the brain and gut--a short reviewJ Physiol PharmacolYear: 200354Suppl 473915075450
116.. Degen L,Drewe J,Piccoli F,Gräni K,Oesch S,Bunea R,et al. Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in menAm J Physiol Regul Integr Comp PhysiolYear: 2007292R1391917138722
117.. Antin J,Gibbs J,Holt J,Young RC,Smith GP. Cholecystokinin elicits the complete behavioral sequence of satiety in ratsJ Comp Physiol PsycholYear: 197589784901176672
118.. Lieverse RJ,Jansen JB,Masclee AA,Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humansGutYear: 19953617697883212
119.. Covasa M,Marcuson JK,Ritter RC. Diminished satiation in rats exposed to elevated levels of endogenous or exogenous cholecystokininAm J Physiol Regul Integr Comp PhysiolYear: 2001280R331711208559
120.. Adrian TE,Bloom SR,Bryant MG,Polak JM,Heitz PH,Barnes AJ. Distribution and release of human pancreatic polypeptideGutYear: 19761794044828120
121.. Larsson LI,Sundler F,Håkanson R. Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cellsCell Tissue ResYear: 1975156167711091353
122.. Schwartz TW,Holst JJ,Fahrenkrug J,Jensen SL,Nielsen OV,Rehfeld JF,et al. Vagal, cholinergic regulation of pancreatic polypeptide secretionJ Clin InvestYear: 1978617819641155
123.. Michel MC,Beck-Sickinger A,Cox H,Doods HN,Herzog H,Larhammar D,et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptorsPharmacol RevYear: 199850143509549761
124.. Asakawa A,Inui A,Yuzuriha H,Ueno N,Katsuura G,Fujimiya M,et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balanceGastroenterologyYear: 2003124132536
125.. Batterham RL,Le Roux CW,Cohen MA,Park AJ,Ellis SM,Patterson M,et al. Pancreatic polypeptide reduces appetite and food intake in humansJ Clin Endocrinol MetabYear: 20038839899212915697
126.. Jesudason DR,Monteiro MP,McGowan BM,Neary NM,Park AJ,Philippou E,et al. Low-dose pancreatic polypeptide inhibits food intake in manBr J NutrYear: 200797426917313701
127.. Berntson GG,Zipf WB,O’Dorisio TM,Hoffman JA,Chance RE. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndromePeptidesYear: 1993144975038332550
128.. Liu YL,Semjonous NM,Murphy KG,Ghatei MA,Bloom SR. The effects of pancreatic polypeptide on locomotor activity and food intake in miceInt J Obes (Lond)Year: 2008321712518779824
129.. Tan TM,Field BC,Minnion JS,Cuenco-Shillito J,Chambers ES,Zac-Varghese S,et al. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420Br J Clin PharmacolYear: 201273232921834938
130.. Carraway R,Leeman SE. Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomachJ Biol ChemYear: 1976251704552993203
131.. Kitabgi P. Prohormone convertases differentially process pro-neurotensin/neuromedin N in tissues and cell linesJ Mol Med (Berl)Year: 2006846283416688434
132.. Feurle GE,Müller B,Rix E. Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in ratsGutYear: 198728Suppl19233692307
133.. Wood JG,Hoang HD,Bussjaeger LJ,Solomon TE. Neurotensin stimulates growth of small intestine in ratsAm J PhysiolYear: 1988255G81373202174
134.. Rosell S,Rökaeus A. The effect of ingestion of amino acids, glucose and fat on circulating neurotensin-like immunoreactivity (NTLI) in manActa Physiol ScandYear: 197910726367539456
135.. Sandoval SL,Kulkosky PJ. Effects of peripheral neurotensin on behavior of the ratPharmacol Biochem BehavYear: 199241385901574529
136.. Cooke JH,Patterson M,Patel SR,Smith KL,Ghatei MA,Bloom SR,Murphy KG. Peripheral and central administration of xenin and neurotensin suppress food intake in rodentsObesity (Silver Spring)Year: 20091711354319214175
137.. Schmidt PT,Näslund E,Grybäck P,Jacobsson H,Hartmann B,Holst JJ,Hellström PM. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satietyRegul PeptYear: 200311621514599711
138.. Scott RB,Kirk D,MacNaughton WK,Meddings JB. GLP-2 augments the adaptive response to massive intestinal re-section in ratAm J PhysiolYear: 1998275G911219815019
139.. Chance WT,Balasubramaniam A,Stallion A,Fischer JE. Anorexia following the systemic injection of amylinBrain ResYear: 199360718588097662
140.. Lutz TA,Del Prete E,Scharrer E. Reduction of food intake in rats by intraperitoneal injection of low doses of amylinPhysiol BehavYear: 19945589158022910
141.. Ratner R,Whitehouse F,Fineman MS,Strobel S,Shen L,Maggs DG,et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targetsExp Clin Endocrinol DiabetesYear: 200511319920415891954
142.. Rushing PA,Hagan MM,Seeley RJ,Lutz TA,Woods SC. Amylin: a novel action in the brain to reduce body weightEndocrinologyYear: 2000141850310650969
143.. Whitehouse F,Kruger DF,Fineman M,Shen L,Ruggles JA,Maggs DG,et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesDiabetes CareYear: 2002257243011919132
144.. Ghourab S,Beale KE,Semjonous NM,Simpson KA,Martin NM,Ghatei MA,et al. Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intakeRegul PeptYear: 201117281521802451
145.. James WP,Caterson ID,Coutinho W,Finer N,Van Gaal LF,Maggioni AP,et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjectsN Engl J MedYear: 20103639051720818901
146.. Christensen R,Kristensen PK,Bartels EM,Bliddal H,Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trialsLancetYear: 200737017061318022033
147.. Rucker D,Padwal R,Li SK,Curioni C,Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysisBMJYear: 20073351194918006966
148.. Adams TD,Gress RE,Smith SC,Halverson RC,Simper SC,Rosamond WD,et al. Long-term mortality after gastric bypass surgeryN Engl J MedYear: 20073577536117715409
149.. Sjöström L,Narbro K,Sjöström CD,Karason K,Larsson B,Wedel H,et al. Effects of bariatric surgery on mortality in Swedish obese subjectsN Engl J MedYear: 20073577415217715408
150.. Dixon AF,Dixon JB,O’Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover studyJ Clin Endocrinol MetabYear: 200590813915585553
151.. Kenler HA,Brolin RE,Cody RP. Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypassAm J Clin NutrYear: 19905287922360554
152.. Chan JL,Heist K,DePaoli AM,Veldhuis JD,Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy menJ Clin InvestYear: 200311114092112727933
153.. Mingrone G,Panunzi S,De Gaetano A,Guidone C,Iaconelli A,Leccesi L,et al. Bariatric surgery versus conventional medical therapy for type 2 diabetesN Engl J MedYear: 201236615778522449317
154.. Schauer PR,Kashyap SR,Wolski K,Brethauer SA,Kirwan JP,Pothier CE,et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetesN Engl J MedYear: 201236615677622449319
155.. Bariatric Surgical and Procedural Interventions in the Treatment of Obese Patients with Type 2 DiabetesIDF position statmentInternational Diabetes FederationYear: 2011
156.. Kellum JM,Kuemmerle JF,O’Dorisio TM,Rayford P,Martin D,Engle K,et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplastyAnn SurgYear: 199021176370 discussion 770–1.. 2192696
157.. le Roux CW,Aylwin SJ,Batterham RL,Borg CM,Coyle F,Prasad V,et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parametersAnnSurgYear: 200624310814
158.. le Roux CW,Welbourn R,Werling M,Osborne A,Kokkinos A,Laurenius A,et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypassAnn SurgYear: 2007246780517968169
159.. le Roux CW,Borg C,Wallis K,Vincent RP,Bueter M,Goodlad R,et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferationAnn SurgYear: 201025250620562614
160.. Chambers AP,Jessen L,Ryan KK,Sisley S,Wilson-Pérez HE,Stefater MA,et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in ratsGastroenterologyYear: 2011141950821699789
161.. Neary NM,Small CJ,Druce MR,Park AJ,Ellis SM,Semjonous NM,et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively 2EndocrinologyYear: 20051465120716150917
162.. Field BC,Wren AM,Peters V,Baynes KC,Martin NM,Patterson M,et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humansDiabetesYear: 2010591635920357366
163.. Daugaard JR,Meier E,Riber D,Bæk CÆ,Larsen KS. The new dual Glucagon-GLP-1 Agonist ZP2929 improves glycemic control and reduces body weight in murine models of obesity and type 2 DiabetesPoster at ADAOrlandoMonth: 6 Year: 2010
164.. Chu ZL,Jones RM,He H,Carroll C,Gutierrez V,Lucman A,et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin releaseEndocrinologyYear: 20071482601917289847
165.. Overton HA,Babbs AJ,Doel SM,Fyfe MC,Gardner LS,Griffin G,et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agentsCell MetabYear: 200631677516517404
166.. Jones RM,Leonard JN,Buzard DJ,Lehmann J. GPR119 agonists for the treatment of type 2 diabetesExpert Opin Ther PatYear: 20091913395919780700
167.. Shah U,Kowalski TJ. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disordersVitam HormYear: 2010844154821094910

Article Categories:
  • Review

Keywords: peptide YY (PYY), glucagon-like peptide-1 (GLP-1), glucagon, ghrelin, bariatric surgery, obesity.

Previous Document:  Interrater reliability: the kappa statistic.
Next Document:  Inherited prothrombotic risk factors in children with first ischemic stroke.